Predicting the Immune Response with NeoScreen®
Are you searching for Neo-Epitopes?
Our unique NeoScreen® Assay allows you to identify top neo-epitope candidates.
SARS-CoV-2 Vaccine Efforts
Immunitrack is committed to playing a role in the fight against COVID-19 by applying our epitope immunogenicity prediction technology to support vaccine development.
Our aim is to help our customers predict the immune response. Immunogenicity prediction is a key need in the field of biologics, particularly for cancer vaccines. We want to help our customers to identify “real” epitopes (those that will cause a T-cell response) from pools of potential neo-epitopes generated by sequencing data.
Conversely (e.g., protein/peptide-based therapeutics), there is often a need to predict if an unwanted immune response can occur.Watch video
Immunitrack publishes study in Frontiers in Immunology in collaboration with CCIT-DK, and University of LiverpoolRead More
Postdoctoral researcher Mie Linder Hübbe is appointed Head of Immunology at ImmunitrackRead More
Immunitrack will attend the LSX World Congress in London, 3-4 May 2023Read More
Immunitrack welcomes Yuliu Guo, as new Ph.D. student in bioinformaticsRead More
Moving Biologics Discovery Forward
Immunitrack has a stellar reputation in the field of peptide-MHC manufacture. Communication was prompt and clear. Our MHC tetramers arrived within a short timeframe. This allowed us to do faster iterations on our project.
Immunologist Biotech Company, California
Novozymes Biopharma uses the FcRn from Immunitrack to develop the albumin based half-life extension platform Veltis®. We have tested a number of commercially available FcRn’s in our screening assay developed for identification of albumin variants with improved affinity for FcRn receptor and found that the biotinylated FcRn’s from Immunitrack deliver superior performance. These biotinylated FcRn’s enable a robust immobilization to Streptavidin-biosensors (Octet Red96 from Pall ForteBio) and deliver very consistent and robust data.
Birgitte Andersen Science manager, Novozymes